Skip to main content
Erschienen in: Archives of Orthopaedic and Trauma Surgery 11/2018

26.09.2018 | Handsurgery

Range of motion, postoperative rehabilitation and patient satisfaction in MCP and PIP joints affected by Dupuytren Tubiana stage 1–3: collagenase enzymatic fasciotomy or limited fasciectomy? A clinical study in 52 patients

verfasst von: Franck M. Leclère, Sabine Kohl, Cédric Varonier, Frank Unglaub, Esther Vögelin

Erschienen in: Archives of Orthopaedic and Trauma Surgery | Ausgabe 11/2018

Einloggen, um Zugang zu erhalten

Abstract

Introduction

In Switzerland, collagenase Clostridium histolyticum therapy (CCH) for Dupuytren’s disease was introduced in 2011. This study analyzes possible differences between CCH and limited fasciectomy (LF) in terms of range of motion, patient satisfaction and postoperative rehabilitation.

Materials and methods

This retrospective study included 52 patients with Dupuytren’s disease stage 1–3 according to Tubiana, treated with CCH or LF between January 2012 and December 2013. Complications were analyzed for each patient. The contracture of each treated joint measured on average at the 3 months and up to 2 years follow-up was compared with the preoperative values. The Michigan Hand score was evaluated at 2 years and the patients were asked to subjectively evaluate the outcome of the treatment and whether they would repeat it if necessary. Postoperative rehabilitation was also precisely quantified.

Results

11 minor complications were reported for a complication rate of 29% in the CCH group. No major complications were reported in both groups. In the CCH group, mean MCP joint contracture was, respectively, 44° ± 20°, 9° ± 2° (gain of mobility compared to the preoperative situation 35°, P < 0.001), and 10° ± 3° (gain 34°, P < 0.001), respectively, before, at the 3 months’ control and at the 2-year clinical control. In the LF group, mean MCP joint contracture was, respectively, 30° ± 21°, 2° ± 0.5° (gain 28°, P < 0.001), and 1° ± 0.5° (gain 29°, P < 0.001) for the same control periods. In the CCH group, mean PIP joint contracture was, respectively, 51° ± 21°, 18° ± 3° (gain of mobility compared to the preoperative situation 33°, P < 0.001), and 32° ± 4° (gain 19°, P < 0.001), respectively, before, at the 3 months’ control and at the 2-year clinical control. In the LF group, mean PIP joint contracture was, respectively, 30° ± 20°, 2° ± 0.5° (gain of mobility compared to the preoperative situation 28°, P < 0.001), and 11° ± 4° (gain 19°, P < 0.001) for the same control periods. Outcomes were compared across the LF and CCH groups: surgery performed better than collagenase for PIP joint treatment at early (P < 0.001) and 2-year follow-up (P = 0.004) controls. However, patient satisfaction was higher in the CCH group: 92% were satisfied or very satisfied of the treatment compared to 71% in the LF group. All patients would reiterate the treatment in the CCH group if necessary compared to only 71% in the LF group. Rehabilitation was highly reduced in the CCH group compared to the LF group.

Conclusion

In this study, surgery performed better than collagenase at early and 2-year follow-up in PIP joints and similar in MCP joints. While surgery seems to achieve better results, collagenase is considered in Switzerland as an off-the-shelf therapy that provides consistent results without scars, with shorter rehabilitation time, minor hand therapy, shorter splinting time, and applicability.

Level of evidence and study type

Level III.
Literatur
2.
Zurück zum Zitat Pillukat T, Walle L, Stüber R, Windolf J, van Schoonhoven J (2017) Treatment of recurrent Dupuytren’s disease. Orthopade 46:342–352CrossRefPubMed Pillukat T, Walle L, Stüber R, Windolf J, van Schoonhoven J (2017) Treatment of recurrent Dupuytren’s disease. Orthopade 46:342–352CrossRefPubMed
3.
Zurück zum Zitat Langer MF, Grünert J, Unglaub F, Wieskötter B, Oeckenpöhler S (2017) The fibrousskeleton of the hand: changes with Dupuytren’s contracture. Orthopade 46:303–314CrossRefPubMed Langer MF, Grünert J, Unglaub F, Wieskötter B, Oeckenpöhler S (2017) The fibrousskeleton of the hand: changes with Dupuytren’s contracture. Orthopade 46:303–314CrossRefPubMed
4.
Zurück zum Zitat Oppermann J, Unglaub F, Müller LP, Löw S, Hahn P, Spies CK (2017) Percutaneousneedle aponeurotomy for Dupuytren’s contracture. Orthopade 46:315–320CrossRefPubMed Oppermann J, Unglaub F, Müller LP, Löw S, Hahn P, Spies CK (2017) Percutaneousneedle aponeurotomy for Dupuytren’s contracture. Orthopade 46:315–320CrossRefPubMed
5.
Zurück zum Zitat Dahmen G, Kerckhoff F (1967) Langzeitheobachtungen operativ und konservativ behandelter Dupuytrenscher Kontrakturen. Archiv für orthopädische und Unfall-Chirurgie, mit besonderer Berücksichtigung der Frakturenlehre und der orthopädisch-chirurgischen Technik 3:187–202CrossRef Dahmen G, Kerckhoff F (1967) Langzeitheobachtungen operativ und konservativ behandelter Dupuytrenscher Kontrakturen. Archiv für orthopädische und Unfall-Chirurgie, mit besonderer Berücksichtigung der Frakturenlehre und der orthopädisch-chirurgischen Technik 3:187–202CrossRef
6.
Zurück zum Zitat Hohendorff B, Spies CK, Muller LP, Ries C (2016) Supplementary arthrolysis of the proximal interphalangeal finger joint in Dupuytren’s contracture: primary operation versus revision. Arch Orthop Trauma Surg 136:435–439CrossRefPubMed Hohendorff B, Spies CK, Muller LP, Ries C (2016) Supplementary arthrolysis of the proximal interphalangeal finger joint in Dupuytren’s contracture: primary operation versus revision. Arch Orthop Trauma Surg 136:435–439CrossRefPubMed
7.
Zurück zum Zitat Hohendorff B, Biber F, Sauer H, Ries C, Spies C, Franke J (2016) Supplementary arthrolysis of the proximal interphalangeal joint of fingers in surgical treatment of Dupuytren’s contracture. Oper Orthop Traumatol 28:4–11CrossRefPubMed Hohendorff B, Biber F, Sauer H, Ries C, Spies C, Franke J (2016) Supplementary arthrolysis of the proximal interphalangeal joint of fingers in surgical treatment of Dupuytren’s contracture. Oper Orthop Traumatol 28:4–11CrossRefPubMed
8.
Zurück zum Zitat Lukas B, Lukas M (2016) Flap plasty in advanced Dupuytren’s disease. Oper Orthop Traumatol 28:20–29CrossRefPubMed Lukas B, Lukas M (2016) Flap plasty in advanced Dupuytren’s disease. Oper Orthop Traumatol 28:20–29CrossRefPubMed
9.
Zurück zum Zitat Walle L, Hohendorff B, Pillukat T, van Schoonhoven J (2016) The lateral-dorsaltransposition flap for closure of a palmar soft tissue defect of the proximal phalanx on the little finger after limited fasciectomy in recurrent Dupuytren’s contracture. Oper Orthop Traumatol 28:38–45CrossRefPubMed Walle L, Hohendorff B, Pillukat T, van Schoonhoven J (2016) The lateral-dorsaltransposition flap for closure of a palmar soft tissue defect of the proximal phalanx on the little finger after limited fasciectomy in recurrent Dupuytren’s contracture. Oper Orthop Traumatol 28:38–45CrossRefPubMed
10.
Zurück zum Zitat Spies CK, Müller LP, Skouras E, Bassemir D, Hahn P, Unglaub F (2016) Percutaneous needle aponeurotomy for Dupuytren’s disease. Oper Orthop Traumatol 28:12–19CrossRefPubMed Spies CK, Müller LP, Skouras E, Bassemir D, Hahn P, Unglaub F (2016) Percutaneous needle aponeurotomy for Dupuytren’s disease. Oper Orthop Traumatol 28:12–19CrossRefPubMed
11.
Zurück zum Zitat Spies CK, Langer M, Hahn P, Müller LP, Unglaub F (2018) The treatment of primary arthritis of the finger and thumb joint. Dtsch Arztebl Int 115:269–275PubMed Spies CK, Langer M, Hahn P, Müller LP, Unglaub F (2018) The treatment of primary arthritis of the finger and thumb joint. Dtsch Arztebl Int 115:269–275PubMed
12.
Zurück zum Zitat Hohendorff B, Franke J, Spies CK, Unglaub F, Müller LP, Ries C (2017) Operative treatment of Dupuytren’s contracture: arthrolysis of the proximal interphalangeal finger joint. Orthopade 46:328–335CrossRefPubMed Hohendorff B, Franke J, Spies CK, Unglaub F, Müller LP, Ries C (2017) Operative treatment of Dupuytren’s contracture: arthrolysis of the proximal interphalangeal finger joint. Orthopade 46:328–335CrossRefPubMed
13.
Zurück zum Zitat Arora R, Kaiser P, Kastenberger TJ, Schmiedle G, Erhart S, Gabl M (2016) Injectable collagenase Clostridium histolyticum as a nonsurgical treatment for Dupuytren’s disease. Oper Orthop Traumatol 28:30–37CrossRefPubMed Arora R, Kaiser P, Kastenberger TJ, Schmiedle G, Erhart S, Gabl M (2016) Injectable collagenase Clostridium histolyticum as a nonsurgical treatment for Dupuytren’s disease. Oper Orthop Traumatol 28:30–37CrossRefPubMed
14.
Zurück zum Zitat Zhou C, Hovius SE, Slijper HP, Feitz R, Van Nieuwenhoven CA, Pieters AJ, Selles RW (2015) Collagenase Clostridium histolyticum versus limited fasciectomy for Dupuytren’s contracture: outcomes from a multicenter propensity score matched study. Plast Reconstr Surg 136:87–97CrossRefPubMed Zhou C, Hovius SE, Slijper HP, Feitz R, Van Nieuwenhoven CA, Pieters AJ, Selles RW (2015) Collagenase Clostridium histolyticum versus limited fasciectomy for Dupuytren’s contracture: outcomes from a multicenter propensity score matched study. Plast Reconstr Surg 136:87–97CrossRefPubMed
15.
Zurück zum Zitat Spies CK, Hahn P, Muller LP, Low S, Sellei RM, Oppermann J (2016) The efficacy of open partial aponeurectomy for recurrent Dupuytren’s contracture. Arch Orthop Trauma Surg 136:881–889CrossRefPubMed Spies CK, Hahn P, Muller LP, Low S, Sellei RM, Oppermann J (2016) The efficacy of open partial aponeurectomy for recurrent Dupuytren’s contracture. Arch Orthop Trauma Surg 136:881–889CrossRefPubMed
16.
Zurück zum Zitat Vesper US, Mehling IM, Arsalan-Werner A, Sauerbier M (2017) Primary intervention in Dupuytren’s disease. Orthopade 46:336–341CrossRefPubMed Vesper US, Mehling IM, Arsalan-Werner A, Sauerbier M (2017) Primary intervention in Dupuytren’s disease. Orthopade 46:336–341CrossRefPubMed
17.
Zurück zum Zitat Smeraglia F, Del Buono A (2016) Collagenase Clostridium histolyticum in Dupuytren’s contracture: a systematic review. Br Med Bull 118:149–158CrossRefPubMed Smeraglia F, Del Buono A (2016) Collagenase Clostridium histolyticum in Dupuytren’s contracture: a systematic review. Br Med Bull 118:149–158CrossRefPubMed
18.
Zurück zum Zitat Badalamente MA, Hurst LC (2000) Enzyme injection as nonsurgical treatment of Dupuytren’s disease. J Hand Surg Am 25:629–636CrossRefPubMed Badalamente MA, Hurst LC (2000) Enzyme injection as nonsurgical treatment of Dupuytren’s disease. J Hand Surg Am 25:629–636CrossRefPubMed
19.
Zurück zum Zitat Leclère FM, Mathys L, Vögelin E (2014) Collagenase injection in Dupuytren’s disease, evaluation of the ultrasound assisted technique. Chir Main 33:196–203CrossRefPubMed Leclère FM, Mathys L, Vögelin E (2014) Collagenase injection in Dupuytren’s disease, evaluation of the ultrasound assisted technique. Chir Main 33:196–203CrossRefPubMed
20.
Zurück zum Zitat Knobloch K, Kuehn M, Papst S, Kraemer R, Vogt PM (2011) German standardized translation of the Michigan Hand Outcomes Questionnaire for patient-related outcome measurement in Dupuytren’s disease. Plast Reconstr Surg 128:39e–40eCrossRefPubMed Knobloch K, Kuehn M, Papst S, Kraemer R, Vogt PM (2011) German standardized translation of the Michigan Hand Outcomes Questionnaire for patient-related outcome measurement in Dupuytren’s disease. Plast Reconstr Surg 128:39e–40eCrossRefPubMed
21.
Zurück zum Zitat Chung KC, Pillsbury MS, Walters MR et al (1998) Reliability and validity testing of the Michigan Hand Outcomes Questionnaire. J Hand Surg (Am) 23:575–587CrossRef Chung KC, Pillsbury MS, Walters MR et al (1998) Reliability and validity testing of the Michigan Hand Outcomes Questionnaire. J Hand Surg (Am) 23:575–587CrossRef
22.
Zurück zum Zitat Dominguez-Malagon HR, Alferian-Ruiz A, Chavarria-Xicotencatl P, Duran-Hernandez (1992) Clinical and cellular effects of colchicine in fibromatosis. Cancer 69:2478–2483CrossRefPubMed Dominguez-Malagon HR, Alferian-Ruiz A, Chavarria-Xicotencatl P, Duran-Hernandez (1992) Clinical and cellular effects of colchicine in fibromatosis. Cancer 69:2478–2483CrossRefPubMed
23.
Zurück zum Zitat Pittet B, Rubia-Brandt L, Desmoulière A, Qappino AP, Roggero P, Guerret S et al (1994) Effects of gamma-interferon on clinical and biologic evolution of hypertrophic scars and Dupuytren’s disease: an open pilot study. Plast Reconstr Surg 93:1224–1235CrossRefPubMed Pittet B, Rubia-Brandt L, Desmoulière A, Qappino AP, Roggero P, Guerret S et al (1994) Effects of gamma-interferon on clinical and biologic evolution of hypertrophic scars and Dupuytren’s disease: an open pilot study. Plast Reconstr Surg 93:1224–1235CrossRefPubMed
24.
Zurück zum Zitat Falter Herndl E, Mulbauer (1991) Dupuytren’s contracture: when operate? Conservative preliminary treatment? Fortschr Med 109:223–226PubMed Falter Herndl E, Mulbauer (1991) Dupuytren’s contracture: when operate? Conservative preliminary treatment? Fortschr Med 109:223–226PubMed
25.
Zurück zum Zitat Keilholz L, Seegenschmeidt MH, Sauer R (1996) Radiotherapy for prevention of disease progression in early stage Dupuytren’s contracture: initial and long-term results. Int J Radiat Oncol Biol Phys 36:891–897CrossRefPubMed Keilholz L, Seegenschmeidt MH, Sauer R (1996) Radiotherapy for prevention of disease progression in early stage Dupuytren’s contracture: initial and long-term results. Int J Radiat Oncol Biol Phys 36:891–897CrossRefPubMed
26.
Zurück zum Zitat Stiles PJ (1966) Ultrasonic therapy in Dupuytren’s. J Bone Jt Surg Br 48:452–454CrossRef Stiles PJ (1966) Ultrasonic therapy in Dupuytren’s. J Bone Jt Surg Br 48:452–454CrossRef
27.
Zurück zum Zitat Vuopala U, Kaipainen (1971) DMOS in the treatment of Dupuytren’s contracture. A therapeutic experiment. Acta Rheumatol Scand 17:61–62CrossRefPubMed Vuopala U, Kaipainen (1971) DMOS in the treatment of Dupuytren’s contracture. A therapeutic experiment. Acta Rheumatol Scand 17:61–62CrossRefPubMed
28.
Zurück zum Zitat Weinzierl G, Flügel M, Geldmacher J (1993) Lack of effectiveness of alternative nonsurgical treatment procedures of Dupuytren contracture. Chirurgie 64:492–494 Weinzierl G, Flügel M, Geldmacher J (1993) Lack of effectiveness of alternative nonsurgical treatment procedures of Dupuytren contracture. Chirurgie 64:492–494
29.
Zurück zum Zitat Kirk JE, Cheiffi M (1952) Tocopherol administration to patients with Dupuytren’s contracture: effect on plasma tocopherol levels and degree of contracture. Proc Soc Exp Biol Med 80:565–568CrossRefPubMed Kirk JE, Cheiffi M (1952) Tocopherol administration to patients with Dupuytren’s contracture: effect on plasma tocopherol levels and degree of contracture. Proc Soc Exp Biol Med 80:565–568CrossRefPubMed
30.
Zurück zum Zitat Dahmen G, Kerckhoff (1966) Possibilities and limitations of the conservative treatment of Dupuytren’s contracture. Med Monatsschr 20:297–300PubMed Dahmen G, Kerckhoff (1966) Possibilities and limitations of the conservative treatment of Dupuytren’s contracture. Med Monatsschr 20:297–300PubMed
31.
Zurück zum Zitat Howard LD Jr, Pratt DR, Bunnell (1953) The use of compound F (hydrocortisone) in operative and non-operative conditions of the hand. J Bone Jt Surg Am 35:994–1002CrossRef Howard LD Jr, Pratt DR, Bunnell (1953) The use of compound F (hydrocortisone) in operative and non-operative conditions of the hand. J Bone Jt Surg Am 35:994–1002CrossRef
32.
Zurück zum Zitat Bassot J (1965) Treatment of Dupuytren’s disease by isolated pharmacodynamic “exeresis” or “exeresis” completed by a solely cutaneous plastic step. Lille Chir 20:38–44PubMed Bassot J (1965) Treatment of Dupuytren’s disease by isolated pharmacodynamic “exeresis” or “exeresis” completed by a solely cutaneous plastic step. Lille Chir 20:38–44PubMed
34.
35.
Zurück zum Zitat Hurst LC, Badalamente MA, Hentz VR, Hotchkiss RN, Kaplan FT, Meals RA, Smith TM, Rodzvilla J, CORD I Study Group (2009) Injectable collagenase Clostridium histolyticum for Dupuytren’s contracture. N Engl J Med 361:968–979CrossRefPubMed Hurst LC, Badalamente MA, Hentz VR, Hotchkiss RN, Kaplan FT, Meals RA, Smith TM, Rodzvilla J, CORD I Study Group (2009) Injectable collagenase Clostridium histolyticum for Dupuytren’s contracture. N Engl J Med 361:968–979CrossRefPubMed
36.
Zurück zum Zitat Gilpin D, Coleman S, Hall S, Houston A, Karrasch J, Jones N (2010) Injectable collagenase Clostridium histolyticum: a new nonsurgical treatment for Dupuytren’s disease. J Hand Surg Am 35:2027–2038CrossRefPubMed Gilpin D, Coleman S, Hall S, Houston A, Karrasch J, Jones N (2010) Injectable collagenase Clostridium histolyticum: a new nonsurgical treatment for Dupuytren’s disease. J Hand Surg Am 35:2027–2038CrossRefPubMed
37.
Zurück zum Zitat Sanjuan Cerveró R, Franco Ferrando N, Poquet Jornet J (2013) Use of resources and costs associated with the treatment of Dupuytren’s contracture at an orthopedics and traumatology surgery department in Denia (Spain): collagenase Clostridium hystolyticum versus subtotal fasciectomy. BMC Musculoskelet Disord 14:293CrossRefPubMed Sanjuan Cerveró R, Franco Ferrando N, Poquet Jornet J (2013) Use of resources and costs associated with the treatment of Dupuytren’s contracture at an orthopedics and traumatology surgery department in Denia (Spain): collagenase Clostridium hystolyticum versus subtotal fasciectomy. BMC Musculoskelet Disord 14:293CrossRefPubMed
38.
Zurück zum Zitat Coleman S, Gilpin D, Kaplan FT, Houston A, Kaufman GJ, Cohen BM, Jones N, Tursi JP (2014) Efficacy and safety of concurrent collagenase Clostridium histolyticum injections for multiple Dupuytren contractures. J Hand Surg Am 39:57–64CrossRefPubMed Coleman S, Gilpin D, Kaplan FT, Houston A, Kaufman GJ, Cohen BM, Jones N, Tursi JP (2014) Efficacy and safety of concurrent collagenase Clostridium histolyticum injections for multiple Dupuytren contractures. J Hand Surg Am 39:57–64CrossRefPubMed
39.
Zurück zum Zitat McMahon HA, Bachoura A, Jacoby SM, Zelouf DS, Culp RW, Osterman AL (2013) Examining the efficacy and maintenance of contracture correction after collagenase Clostridium histolyticum treatment for Dupuytren’s disease. Hand (NY) 8:261–266CrossRef McMahon HA, Bachoura A, Jacoby SM, Zelouf DS, Culp RW, Osterman AL (2013) Examining the efficacy and maintenance of contracture correction after collagenase Clostridium histolyticum treatment for Dupuytren’s disease. Hand (NY) 8:261–266CrossRef
40.
Zurück zum Zitat Gaston RG, Larsen SE, Pess GM, Coleman S, Dean B, Cohen BM, Kaufman GJ, Tursi JP, Hurst LC (2015) The efficacy and safety of concurrent collagenase Clostridium histolyticum injections for 2 Dupuytren contractures in the same hand: a prospective, multicenter study. J Hand Surg Am 40:1963–1971CrossRefPubMed Gaston RG, Larsen SE, Pess GM, Coleman S, Dean B, Cohen BM, Kaufman GJ, Tursi JP, Hurst LC (2015) The efficacy and safety of concurrent collagenase Clostridium histolyticum injections for 2 Dupuytren contractures in the same hand: a prospective, multicenter study. J Hand Surg Am 40:1963–1971CrossRefPubMed
41.
Zurück zum Zitat Badalamente MA, Hurst LC, Benhaim P, Cohen BM (2015) Efficacy and safety of collagenase Clostridium histolyticum in the treatment of proximal interphalangeal joints in dupuytren contracture: combined analysis of 4 phase 3 clinical trials. J Hand Surg Am 40:975–983CrossRefPubMed Badalamente MA, Hurst LC, Benhaim P, Cohen BM (2015) Efficacy and safety of collagenase Clostridium histolyticum in the treatment of proximal interphalangeal joints in dupuytren contracture: combined analysis of 4 phase 3 clinical trials. J Hand Surg Am 40:975–983CrossRefPubMed
42.
Zurück zum Zitat Degreef I (2016) Collagenase treatment in Dupuytren contractures: a review of the current state versus future needs. Rheumatol Ther 3:43–51CrossRefPubMed Degreef I (2016) Collagenase treatment in Dupuytren contractures: a review of the current state versus future needs. Rheumatol Ther 3:43–51CrossRefPubMed
43.
Zurück zum Zitat Gajendran VK, Hentz V, Kenney D, Curtin CM (2014) Multiple collagenase injections are safe for treatment of Dupuytren’s contractures. Orthopedics 37:657–660CrossRef Gajendran VK, Hentz V, Kenney D, Curtin CM (2014) Multiple collagenase injections are safe for treatment of Dupuytren’s contractures. Orthopedics 37:657–660CrossRef
44.
Zurück zum Zitat Van Beeck A, Van den Broek M, Michielsen M, Didden K, Vuylsteke K, Verstreken F (2017) Efficacy and safety of collagenase treatment for Dupuytren’s disease: 2-year follow-up results. Hand Surg Rehabil 36:346–349 (Epub Jul 18) CrossRefPubMed Van Beeck A, Van den Broek M, Michielsen M, Didden K, Vuylsteke K, Verstreken F (2017) Efficacy and safety of collagenase treatment for Dupuytren’s disease: 2-year follow-up results. Hand Surg Rehabil 36:346–349 (Epub Jul 18) CrossRefPubMed
Metadaten
Titel
Range of motion, postoperative rehabilitation and patient satisfaction in MCP and PIP joints affected by Dupuytren Tubiana stage 1–3: collagenase enzymatic fasciotomy or limited fasciectomy? A clinical study in 52 patients
verfasst von
Franck M. Leclère
Sabine Kohl
Cédric Varonier
Frank Unglaub
Esther Vögelin
Publikationsdatum
26.09.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Orthopaedic and Trauma Surgery / Ausgabe 11/2018
Print ISSN: 0936-8051
Elektronische ISSN: 1434-3916
DOI
https://doi.org/10.1007/s00402-018-3034-6

Weitere Artikel der Ausgabe 11/2018

Archives of Orthopaedic and Trauma Surgery 11/2018 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Arthroskopie kann Knieprothese nicht hinauszögern

25.04.2024 Gonarthrose Nachrichten

Ein arthroskopischer Eingriff bei Kniearthrose macht im Hinblick darauf, ob und wann ein Gelenkersatz fällig wird, offenbar keinen Unterschied.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.